GSK2801 is primarily utilized in the field of biomedical research, particularly in the study of epigenetic regulation. It serves as a potent and selective inhibitor of the bromodomain-containing protein BRD9, which is involved in chromatin remodeling and gene expression. Researchers employ GSK2801 to investigate the role of BRD9 in various biological processes, including cancer progression and immune response. By inhibiting BRD9, this compound helps elucidate the mechanisms underlying diseases and aids in the development of targeted therapies. Additionally, GSK2801 is used in high-throughput screening assays to identify potential drug candidates for conditions where BRD9 activity is implicated. Its specificity and efficacy make it a valuable tool in understanding epigenetic pathways and advancing therapeutic innovations.